Copyright
©The Author(s) 2021.
World J Psychiatr. Aug 19, 2021; 11(8): 463-476
Published online Aug 19, 2021. doi: 10.5498/wjp.v11.i8.463
Published online Aug 19, 2021. doi: 10.5498/wjp.v11.i8.463
Ref. | Sample size (sex) melatonin; control | Age (yr) melatonin; control | Dose, duration | Diagnosis | Inclusion criteria | Study design | Outcomes | Significant findings | Risk of bias |
Baandrup et al[12], 2016 | 42 (23 M, 19 F); 44 (25 M, 19 F) | 47.9 ± 8.7; 49.4 ± 12.3 | 2 mg/d PR melatonin or placebo for 24 wk | Paranoid SCZ (n = 67), Non-paranoid SCZ (n = 6), SZA (n = 3), BP (n = 10) | Diagnosis of SCZ, SZA or BP (as per ICD-10 criteria); treated with 1 antipsychotic drug and 1 BZD drug for 3 mo; able to understand Danish | Randomized, double-blind clinical trial | Mean daily dosage of BZD, pattern of BZD dosage, BZD cessation proportion, BWSQ-2 | - | Some concerns |
- Citation: Duan C, Jenkins ZM, Castle D. Therapeutic use of melatonin in schizophrenia: A systematic review. World J Psychiatr 2021; 11(8): 463-476
- URL: https://www.wjgnet.com/2220-3206/full/v11/i8/463.htm
- DOI: https://dx.doi.org/10.5498/wjp.v11.i8.463